GLIVEC 400 MG 30 F.C.TABS

About Imatinib Anticancer Tyrosine- kinase inhibitor First generation. Mechanism of Action of Imatinib Imatinib is an inhibitor of multiple tyrosine kinases including Kit abl and PDGFR( platelet-derived growth factor receptor) and inhibit phosphorelation. Indications for Imatinib 1.Chronic myelogenous leukemia 2.Lymphoblastic leukemia (PH+ALL) 3.Gastrointestinal stromal tumors 4.Systemic mastocytosis 5.Hypereosinophilic syndrome 6.Dermatofibrosarcoma protuberans. 7.Plexiform neurofibromas Interactions for Imatinib CYP3A4 inhibitors e.g. ketoconazole erythromycin clarithromycin itraconazole grapefruit juice)---- decrease metabolism---- increase Imatinib exposure (40%) CYP3A4 inducers (dexamethasone phenytoin carbamazepine rifampicin phenobarbital or St. John?s Wort)----- increase metabolism---- decrease Imatinib exposure (74%) CYP2D6 inhibitors (e.g. doxorubicin quinidine vinca alkaloids dextropropoxyphene)---- decrease metabolism---- increased